Migrainous Infarction: Rare Stroke Complication of Migraine with Aura
Definition
Migrainous infarction (MI) is an ischemic stroke occurring during a typical migraine with aura attack, with neuroimaging confirmation of infarct in a relevant territory, and not attributable to other causes. ICHD-3 criteria require:
- Migraine with aura attack.
- One or more aura symptoms persisting >60 minutes.
- Neuroimaging shows ischemic infarct in corresponding territory.
- Other causes excluded (cardioembolic, large vessel, small vessel, other determined/undetermined).
Epidemiology
- Extremely rare: ~0.2–0.5% of all ischemic strokes; ~2–4 per 100,000 person-years.
- Predominantly young women (mean age 30–40) with migraine with aura.
- Posterior circulation (vertebrobasilar) slightly more common than anterior.
Pathophysiology (Hypothesized)
- Cortical spreading depression (CSD): Prolonged depolarization → metabolic stress, oxidative injury, blood-brain barrier disruption.
- Vasoconstriction: CSD-induced oligemia may progress to ischemia in vulnerable territories.
- Hypercoagulability: Platelet activation, elevated vWF, reduced protein S during attacks.
- Endothelial dysfunction: Impaired vasoreactivity, pro-thrombotic state.
- Vascular anatomy: Hypoplastic vertebral/basilar artery, PFO (paradoxical embolism).
Clinical Presentation
- Aura symptoms (visual, sensory, speech) that do not resolve within typical 60-minute window.
- New focal deficits (hemiparesis, ataxia, dysarthria, visual field loss) coinciding with aura.
- Headache may be less prominent than neurologic deficit.
Diagnosis
- Emergent MRI brain (DWI/FLAIR) — gold standard for acute infarct.
- MRA/CTA — vessel imaging.
- Cardiac workup (echo, Holter, PFO assessment).
- Hypercoagulable panel (especially if unprovoked).
- Exclude mimics: MELAS, CADASIL, mitochondrial disorders, vasculitis.
Acute Management
- IV thrombolysis (alteplase/tenecteplase): If within 4.5 hours of symptom onset and no contraindications. Benefit likely outweighs theoretical hemorrhage risk from CSD.
- Mechanical thrombectomy: If large vessel occlusion (LVO) identified.
- Avoid: Triptans, ergotamines, vasoconstrictors.
- Antiplatelet/anticoagulation per stroke etiology (aspirin, DOAC if cardioembolic).
- Admission to stroke unit; neurology + headache specialist co-management.
Secondary Prevention
- High-efficacy migraine preventive (CGRP mAb, topiramate, beta-blocker) to reduce aura frequency.
- Aggressive vascular risk factor control (BP, lipids, glucose, smoking).
- Estrogen avoidance (if aura).
- Antiplatelet therapy (aspirin 81 mg daily) often recommended long-term.
- Consider PFO closure if recurrent cryptogenic stroke + PFO (per RESPECT/CLOSE criteria).
Prognosis
Generally favorable if small infarct; higher recurrence risk than general population. Long-term multidisciplinary follow-up essential.
Migraine - Related Articles
- Migraines with Aura: Causes, Symptoms & What to Do
- Can Migraine Cause a Fever? Understanding the Connection and Management
- Quinine for Migraine: Efficacy, Dosing, Risks, and Why It's Not First-Line
- Migraine Medications: Types, Treatments & Relief
- Migraine Pathophysiology: The Role of Vasodilation in Pain Generation
- Triptans (Serotonin Receptor Agonists) for Acute Migraine Treatment
- Migraine Aura: Understanding Symptoms & Causes
